Multivariate distributions of clinical covariates at the time of cancer detection

Statistical Methods in Medical Research

Volumn 13, Issue 6, 2004, Pages 457-489

  Hanin, L G ^a   Yakovlev, A Y ^b  

^a Nucl Eng Idaho State University   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; AWARENESS; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER MODEL; CANCER PATIENT; CANCER SCREENING; CLINICAL PROTOCOL; HUMAN; INFORMATION PROCESSING; LATENT PERIOD; MATHEMATICAL MODEL; METHODOLOGY; MULTIVARIATE ANALYSIS OF COVARIANCE; OBSERVATION; PROSTATE CANCER; PUBLIC HEALTH SERVICE; QUANTITATIVE ANALYSIS; STATISTICAL MODEL; STATISTICAL PARAMETERS; TUMOR VOLUME;

AGED; EARLY DIAGNOSIS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 9444271755     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/0962280204sm378ra     Document Type: Article

References (63)

1. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001; 358: 1340-42.
2. Retsky M, Demicheli R, Hrushesky W. Breast cancer screening: controversies and future directions. Current Opinion in Obstetrics and Gynecology 2003; 15: 1-8.
3. Asselain B, Fourquet A, Hoang T, Tsodikov A, Yakovlev AY. A parametric regression model of tumor recurrence: an application to the analysis of clinical data on breast cancer. Statistics and Probability Letters 1996; 29: 271-78.
4. Tsodikov A. Semiparametric models of long- and short-term survival: an application to the analysis of breast cancer survival in Utah by age and stage. Statistics in Medicine 2002; 21: 895-920.
5. Tsodikov AD, Ibrahim JG, Yakovlev AY. Estimating cure rates from survival data: an alternative to two-component mixture models. Journal of the American Statistical Association 2003; 98: 1063-78.
6. Tsodikov AD, Müller WA. Modeling carcinogenesis under a time-changing exposure. Mathematical Biosciences 1998; 152: 179-91.
7. Yakovlev AY, Tsodikov AD, Boucher K, Kerber R. The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer 1999; 85: 1789-98.
8. Zaider M, Zelefsky MJ, Hanin LG, Tsodikov AD, Yakovlev AY, Leibel SA. A survival model for fractionated radiotherapy with an application to prostate cancer. Physics in Medicine and Biology 2001; 46: 2745-58.
9. van den Akker-van Marle ME, Reep-van den Berch CMM, Moral AD, Ascunce N, De Koning HJ. Breast cancer screening in Navarra: interpretation of a high detection rate at the first screening round and a low rate at the second round. International Journal of Cancer 1997; 73: 464-69.
10. Albert A, Gertman PM, Louis TA. Screening for the early detection of cancer. I. The temporal history of a progressive disease state. Mathematical Biosciences 1978; 40: 1-59.
11. Albert A, Gertman PM, Louis TA, Liu SI. Screening for the early detection of cancer. II. The impact of the screening on the natural history of the disease. Mathematical Biosciences 1978; 40: 61-109.
12. Blumenson LE. When is screening effective in reducing the death rate? Mathematical Biosciences 1976; 30: 273-303.
13. Blumenson LE. Detection of disease with periodic screening: transient analysis and application to mammography examination. Mathematical Biosciences 1977; 33: 73-106.
14. Brookmeyer R, Day N. Two-stage model for the analysis of cancer screening data. Biometrics 1987; 43: 657-69.
15. Chen HH, Duffy SW, Tabar L. A Markov chain method to estimate the tumor progression rate from preclinical to clinical phase, sensitivity and positive predictive value for mammography in breast cancer screening. The Statistician 1996; 45: 307-17.
16. Cronin KA, Legler JM, Etzioni RD. Assessing uncertainty in microsimulation modelling with application to cancer screening interventions. Statistics in Medicine 1998; 17: 2509-23.
17. Day NE, Walter SD. Simplified models of screening for chronic disease. Estimation procedures from mass screening programs. Biometrics 1984; 40: 1-14.
18. Duffy SW, Chen HH, Tabar L, Day NE. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Statistics in Medicine 1995; 14: 1531-43.
19. Eddy DM. A mathematical model for timing repeated medical tests. Medical Decision Making 1983; 3: 34-62.
20. Pearson JD, Morrell CH, Landis PK, Carter HB, Brant LJ. Mixed-effects regression models for studying the natural history of prostate disease. Statistics in Medicine 1994; 13: 587-601.
21. Flehinger BJ, Kimmel M. The natural history of lung cancer in a periodically screened population. Biometrics 1987; 43: 127-44.
22. Flehinger BJ, Kimmel M. Screening for cancer in relation to the natural history of the disease, In Arino O, Axelrod DE, Kimmel M eds. Mathematical population dynamics. New York: Marcel Dekker, 1991: 383-90.
23. Flehinger BJ, Kimmel M, Melamed MR. The natural history of adenocarcinoma/large cell carcinoma of lung: conclusions from screening programs in New York and Baltimore. Journal of the National Cancer Institute 1988; 80: 337-44.
24. Hu P, Zelen M. Planning clinical trials to evaluate early detection programmes. Biometrika 1997; 84: 817-29.
25. Kirch R, Klein M. Surveillance schedules for medical examinations. Management Science 1974; 20: 1403-409.
26. Lee SJ, Zelen M. Scheduling periodic examinations for the early detection of disease: applications to breast cancer. Journal of the American Statistical Association 1998; 93: 1271-81.
27. Louis T, Albert A, Heghinian S. Screening for the early detection of cancer. III. Estimation of disease natural history, Mathematical Biosciences 1978; 40: 111-44.
28. van Oortmarssen G, Evaluation of mass screening for cancer: a model-based approach. Alblasserdam, The Netherlands: Offsetdrukkerij, 1995.
29. Parmigiani G. (1992). Optimal scheduling of fallible inspections, DP 92-A38, ISDS, Duke University.
30. Parmigiani G. On optimal screening ages. Journal of the American Statistical Association 1993; 88: 622-28.
31. Parmigiani G. Timing medical examinations via intensity functions. Biometrika 1997; 84: 803-16.
32. Pinsky PF. Estimation and prediction for cancer screening models using deconvolution and smoothing. Biometrics 2001; 57 389-95.
33. Prorok PC. The theory of periodic screening. I: lead time and proportion detected. Advances in Applied Probability 1976; 8: 127-43.
34. Prorok PC. The theory of periodic screening. II: doubly bounded recurrence times and mean lead time and detection probability estimation. Advances in Applied Probability 1976; 8: 460-76.
35. Schwartz M. An analysis of the benefits of serial screening for breast cancer based upon a mathematical model of the disease. Cancer 1978; 41: 1550-64.
36. Schwartz M. A mathematical model used to analyse breast cancer screening strategies. Operations Research 1978; 26: 937-55.
37. Shahani AK, Crease DM. Towards models of screening for early detection of disease. Advances in Applied Probability 1977; 9 665-80.
38. Shen Y, Zelen M. Parametric estimation procedures for screening programmes: stable and nonstable disease models for multimodality case finding. Biometrika 1999; 86: 503-15.
39. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. Journal of Clinical Oncology 2001; 19: 3490-99.
40. Tsodikov AD. Screening under uncertainty. Games approach, Systems Analysis, Modelling and Simulation 1992; 9: 259-62.
41. Tsodikov AD, Yakovlev AY. On the optimal policies of cancer screening. Mathematical Biosciences 1991; 107: 21-45.
42. Walter SD, Day NE. Estimation of the duration of a preclinical state using screening data. American Journal of Epidemiology 1983; 118: 865-86.
43. Yakovlev AY, Tsodikov AD. Stochastic models of tumor latency and their biostatistical applications. Singapore: World Scientific Publ., 1996.
44. Zelen M. Optimal scheduling of examinations for the early detection of disease. Biometrika 1993; 80: 279-93.
45. Zelen M, Feinleib M. On the theory of screening for chronic disease. Biometrika 1969; 56: 601-14.
46. Tsodikov AD, Asselain B, Fourquet A, Hoang T, Yakovlev AY. Discrete strategies of cancer post-treatment surveillance. Estimation and optimization problems. Biometrics 1995; 51: 437-47.
47. Boucher KM, Kerber RA. The shape of the hazard function for cancer incidence. Mathematical and Computer Modelling 2001; 33 1361-76.
48. Gregori G, Hanin LG, Luebeck EG, Moolgavkar SH, Yakovlev AY. Testing goodness of fit for stochastic models of carcinogenesis. Mathematical Biosciences 2002; 175: 13-29.
49. Bartoszyński R, Edler L, Hanin L, Kopp-Schneider A, Pavlova L, Tsodikov A, Zorin A, Yakovlev A. Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis. Mathematical Biosciences 2001; 171: 113-42.
50. Hanin LG. Identification problem for stochastic models with application to carcinogenesis, cancer detection and radiation biology. Discrete Dynamics in Nature and Society 2002; 7, 3: 177-89.
51. Moolgavkar SH, Luebeck EG. Two-event model for carcinogenesis: biological, mathematical and statistical considerations. Risk Analysis 1990; 10: 323-41.
52. Yakovlev AY, Polig E. A diversity of responses displayed by a stochastic model of radiation carcinogenesis allowing for cell death. Mathematical Biosciences 1996; 132: 1-33.
53. Hanin LG, Boucher K. Identification of parameters in the Yakovlev-Polig model of carcinogenesis. Mathematical Biosciences 1999; 160: 1-24.
54. Zelen M. A hypothesis for the natural time history of breast cancer. Cancer Research 1968; 28: 207-16.
55. Feldstein M, Zelen M. Inferring the natural time history of breast cancer: implications for tumor growth rate and early detection. Breast Cancer Research and Treatment 1984; 4: 3-10.
56. Blumenson LE, Bross IDJ. A mathematical analysis of the growth and spread of breast cancer. Biometrics 1969; 22: 95-109.
57. Atkinson NE, Bartoszyński R, Brown BW, Thompson JR. On estimating the growth function of tumors. Mathematical Biosciences 1983; 67: 145-66.
58. Atkinson NE, Brown BW, Thompson JR. On the lack of concordance between primary and secondary tumor growth rates. Journal of the National Cancer Institute 1987; 78: 425-35.
59. Bartoszyński R. A modeling approach to metastatic progression of cancer. In Thompson JR, Brown BW eds. Cancer modeling New York and Basel: Marcel Dekker, 1987: 237-67.
60. Brown BW, Atkinson NE, Bartoszyński R, Montague ED. Estimation of human tumor growth rate from distribution of tumor size at detection. Journal of the National Cancer Institute 1984; 72: 31-38.
61. Klein M, Bartoszyński R. Estimation of growth and metastatic rates of primary breast cancer. In Arino O, Axelrod DE, Kimmel M, eds. Mathematical population dynamics, New York: Marcel Dekker, 1991: 397-412.
62. Hanin LG, Tsodikov AD, Yakovlev AY, Optimal schedules of cancer surveillance and tumor size at detection. Mathematical and Computer Modelling 2001; 33: 1419-30.
63. Zorin AV, Edler L, Hanin LG, Yakovlev AY. Estimating the natural history of breast cancer from bivariate data on age and tumor size at diagnosis. In Edler L. and Kitsos, CP eds. Quantitative methods for cancer and human health risk assessment, New York: Wiley, 2004: in press.